Cite
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
MLA
Cazzaniga, Marina, et al. “Correction 2: Everolimus (EVE) and Exemestane (EXE) in Patients with Advanced Breast Cancer Aged ≥ 65 Years: New Lessons for Clinical Practice from the EVA Study.” Oncotarget, vol. 9, no. 94, Nov. 2018, pp. 36720–21. EBSCOhost, https://doi.org/10.18632/oncotarget.26431.
APA
Cazzaniga, M., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Valerio, M. R., Airoldi, M., Moretti, G., Ficorella, C., Arcangeli, V., Diodati, L., Zambelli, A., Febbraro, A., Generali, D., Pistelli, M., Garrone, O., Musolino, A., Vici, P., Maur, M., … Torri, V. (2018). Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study. Oncotarget, 9(94), 36720–36721. https://doi.org/10.18632/oncotarget.26431
Chicago
Cazzaniga, Marina, Claudio Verusio, Mariangela Ciccarese, Alberto Fumagalli, Donata Sartori, Maria Rosaria Valerio, Mario Airoldi, et al. 2018. “Correction 2: Everolimus (EVE) and Exemestane (EXE) in Patients with Advanced Breast Cancer Aged ≥ 65 Years: New Lessons for Clinical Practice from the EVA Study.” Oncotarget 9 (94): 36720–21. doi:10.18632/oncotarget.26431.